What is Lycera?
Lycera operates at the intersection of immunology and drug discovery, specializing in the development of novel small molecule therapies for cancer and autoimmune diseases. The company leverages a sophisticated research portfolio designed to modulate immune responses, effectively targeting inflammatory pathways. With a robust pipeline that includes wholly owned programs and strategic collaborations with industry giants like Merck, Lycera maintains a strong competitive position. The firm's leadership team integrates deep clinical expertise with commercialization experience, ensuring that their therapeutic candidates are well-positioned for clinical testing and eventual market entry. Their focus on immune cell differentiation and metabolic pathways represents a high-barrier-to-entry niche within the broader biotechnology landscape.
How much funding has Lycera raised?
Lycera has raised a total of $96.2M across 6 funding rounds:
Series A
$36M
Private Equity
$21M
Debt
$5M
Debt
$4M
Series B
$29.9M
Debt
$350K
Series A (2009): $36M with participation from Clarus Ventures, ARCH Venture Partners, EDF Ventures, and InterWest Partners
Private Equity (2012): $21M, investors not publicly disclosed
Debt (2013): $5M supported by InterWest Partners and ARCH Venture Partners
Debt (2014): $4M featuring Clarus Ventures, ARCH Venture Partners, and InterWest Partners
Series B (2015): $29.9M backed by InterWest Partners, ARCH Venture Partners, and Clarus Ventures
Debt (2020): $350K with participation from PPP
Key Investors in Lycera
ARCH Venture Partners
ARCH Venture Partners is a leading earlystage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
Clarus Ventures
Blackstone Life Sciences focuses on bringing vital medicines and technologies to market, aiming to improve patient outcomes through collaboration with pharmaceutical, biotech, and medical technology companies. The firm addresses the funding gap in the life sciences sector by investing in late-stage development of innovative products.
EDF Ventures
EDF Ventures is a leading venture capital firm investing in early-stage healthcare companies, focusing on breakthrough technologies that address large, well-recognized problems or transform existing markets.
What's next for Lycera?
With the recent capital injection, Lycera is poised to advance its lead product candidates through critical clinical milestones. The strategic roadmap emphasizes the transition of its inflammatory bowel disease programs into advanced testing phases, while simultaneously expanding its collaborative research efforts. As the company scales its operations, the focus will remain on validating its proprietary small molecule therapies in human trials. Investors are closely monitoring the firm's ability to translate its deep scientific research into scalable, market-ready medical solutions, which will be pivotal for future growth and potential exit opportunities in the highly competitive biopharma ecosystem.
See full Lycera company page
